modelling vemurafenib resistance melanoma reveals strategy forestall drug resistance
mutational activation braf prevalent genetic alteration human melanoma > % tumours expressing brafv600e oncoprotein moreover marked tumour regression improved survival late-stage braf-mutated melanoma patients response treatment vemurafenib demonstrates essential role oncogenic braf melanoma maintenance however patients relapse lethal drug-resistant disease understanding preventing mechanisms resistance critical providing improved therapy investigate cause consequences vemurafenib resistance using two independently derived primary human melanoma xenograft models drug resistance selected continuous vemurafenib administration one models resistant tumours show continued dependency brafv600e-> mek > erk signalling owing elevated brafv600e expression importantly demonstrate vemurafenib-resistant melanomas become drug dependent continued proliferation cessation drug administration leads regression established drug-resistant tumours demonstrate discontinuous dosing strategy exploits fitness disadvantage displayed drug-resistant cells absence drug forestalls onset lethal drug-resistant disease data highlight concept drug-resistant cells may also display drug dependency altered dosing may prevent emergence lethal drug resistance observations may contribute sustaining durability vemurafenib response ultimate goal curative therapy subset melanoma patients braf mutations
